Clinical perspectives of PSMA PET/MRI for prostate cancer

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author BARBOSA, Felipe de Galiza
QUEIROZ, Marcelo Araujo FMUSP-HC
NUNES, Rafael Fernandes
MARIN, Jose Flavio Gomes FMUSP-HC
BUCHPIGUEL, Carlos Alberto FMUSP-HC
CERRI, Giovanni Guido FMUSP-HC
dc.date.issued 2018
dc.identifier.citation CLINICS, v.73, suppl.1, article ID UNSP e586s, 9p, 2018
dc.identifier.issn 1807-5932
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29418
dc.description.abstract Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including (68)gallium and (18)fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
dc.language.iso eng
dc.publisher HOSPITAL CLINICAS, UNIV SAO PAULO
dc.relation.ispartof Clinics
dc.rights openAccess
dc.subject Prostate Cancer; Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Imaging; Tumor Staging; Local Neoplasm Recurrence
dc.subject.other ga-68-psma ligand pet/ct; treatment response biomarker; contrast-enhanced mri; membrane antigen; radical prostatectomy; bone metastases; gleason score; biochemical recurrence; radiation treatment; solid tumors
dc.title Clinical perspectives of PSMA PET/MRI for prostate cancer
dc.type article
dc.rights.holder Copyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.description.group LIM/43
dc.description.group LIM/44
dc.identifier.doi 10.6061/clinics/2018/e586s
dc.identifier.pmid 30281701
dc.type.category review
dc.type.version publishedVersion
hcfmusp.author QUEIROZ, Marcelo Araujo:HC:ICESP
hcfmusp.author MARIN, Jose Flavio Gomes:HC:ICESP
hcfmusp.author BUCHPIGUEL, Carlos Alberto:FM:MDR
hcfmusp.author CERRI, Giovanni Guido:FM:MDR
hcfmusp.author.external · BARBOSA, Felipe de Galiza:Hosp Sirio Libanes, Dept Radiol, Sao Paulo, SP, Brazil
· NUNES, Rafael Fernandes:Hosp Sirio Libanes, Dept Radiol, Sao Paulo, SP, Brazil
hcfmusp.origem.id WOS:000447865600028
hcfmusp.origem.id 2-s2.0-85054463896
hcfmusp.publisher.city SAO PAULO
hcfmusp.publisher.country BRAZIL
hcfmusp.relation.reference · Afshar-Oromieh A, 2014, EUR J NUCL MED MOL I, V41, P887, DOI 10.1007/s00259-013-2660-z
· Afshar-Oromieh A, 2013, EUR J NUCL MED MOL I, V40, P1629, DOI 10.1007/s00259-013-2489-5
· Artigas C, 2016, EUR J NUCL MED MOL I, V43, P195, DOI 10.1007/s00259-015-3236-x
· Bakht MK, 2017, NUCL MED MOLEC IMAG, V51, P202, DOI 10.1007/s13139-016-0439-4
· Ballas LK, 2016, J NUCL MED, V57, p6S, DOI 10.2967/jnumed.115.170142
· Bates A, 2017, EUR RADIOL, V27, P5290, DOI 10.1007/s00330-017-4877-x
· Baumann R, 2018, STRAHLENTHER ONKOL, V194, P318, DOI 10.1007/s00066-017-1239-1
· Bieth M, 2017, J NUCL MED, V58, P1632, DOI 10.2967/jnumed.116.189050
· Budaus L, 2016, EUR UROL, V69, P393, DOI 10.1016/j.eururo.2015.06.010
· Calais J, 2018, J NUCL MED, V59, P557, DOI 10.2967/jnumed.117.196444
· Calais J, 2018, J NUCL MED, V59, P434, DOI [10.2967/jnumed.117.201749, 10.2967/jnumed.117.202945]
· Ceci F, 2017, EUR J NUCL MED MOL I, V44, pS78, DOI 10.1007/s00259-017-3723-3
· Chaloupka M, 2017, UROL CLIN N AM, V44, P557, DOI 10.1016/j.ucl.2017.07.004
· Collignon J, 2010, PET CLIN, V5, P311, DOI 10.1016/j.cpet.2010.05.002
· De Coster L, 2017, EUR J NUCL MED MOL I, V44, P1607, DOI 10.1007/s00259-017-3712-6
· Dennis ER, 2012, J CLIN ONCOL, V30, P519, DOI 10.1200/JCO.2011.36.5791
· Eiber M, 2014, ABDOM IMAGING, V40, P897
· Eiber M, 2016, EUR UROL SUPPL, V15, pe566, DOI 10.1016/S1569-9056(16)60568-7
· Eiber M, 2017, J NUCL MED, V58, p67S, DOI 10.2967/jnumed.116.186767
· Eiber M, 2016, EUR UROL, V70, P829, DOI 10.1016/j.eururo.2015.12.053
· Eiber M, 2015, ABDOM IMAGING, V40, P1769, DOI 10.1007/s00261-014-0301-z
· Eiber M, 2015, J NUCL MED, V56, P668, DOI 10.2967/jnumed.115.154153
· Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
· Emmett L, 2017, J NUCL MED, V58, P1972, DOI 10.2967/jnumed.117.196683
· Evans MJ, 2011, P NATL ACAD SCI USA, V108, P9578, DOI 10.1073/pnas.1106383108
· Freitag MT, 2018, EUR J NUCL MED MOL I, V45, P340, DOI 10.1007/s00259-017-3854-6
· Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8
· Gorin MA, 2017, PET CLIN, V12, P185, DOI 10.1016/j.cpet.2016.11.001
· Grubmuller B, 2018, EUR J NUCL MED MOL I, V45, P235, DOI 10.1007/s00259-017-3858-2
· Habl G, 2017, PROSTATE, V77, P920, DOI 10.1002/pros.23347
· Hammes J, 2018, J NUCL MED, V59, P1070, DOI 10.2967/jnumed.117.203265
· Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002
· Henkenberens C, 2016, STRAHLENTHER ONKOL, V192, P431, DOI 10.1007/s00066-016-0982-z
· Hicks RJ, 2017, J NUCL MED, V58, P1969, DOI 10.2967/jnumed.117.198812
· Hijazi S, 2015, PROSTATE, V75, P1934, DOI 10.1002/pros.23091
· Hijazi S, 2016, PROSTATE, V76, P776, DOI 10.1002/pros.23168
· Hoeks CMA, 2011, RADIOLOGY, V261, P46, DOI 10.1148/radiol.11091822
· Hotker AM, 2015, EUR RADIOL, V25, P2665, DOI 10.1007/s00330-015-3688-1
· Hofman MS, 2017, PET CLIN, V12, P219, DOI 10.1016/j.cpet.2016.12.004
· Hope TA, 2017, J NUCL MED, V58, P1956, DOI 10.2967/jnumed.117.192476
· Hope TA, 2017, J NUCL MED, V58, P81, DOI 10.2967/jnumed.116.181800
· Instituto Nacional de Cancer Jose Alencar Gomes da Silva (INCA), 2016, EST 2016 INC CANC BR
· Jadvar Hossein, 2005, Mol Imaging, V4, P91
· Jadvar H, 2018, J NUCL MED, V59, P228, DOI 10.2967/jnumed.117.203604
· Jadvar H, 2013, EUR J NUCL MED MOL I, V40, pS5, DOI 10.1007/s00259-013-2361-7
· Janssen JC, 2018, EUR RADIOL, V28, P610, DOI 10.1007/s00330-017-4994-6
· Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
· Koerber SA, 2017, J NUCL MED, V58, P1943, DOI 10.2967/jnumed.117.190314
· Kranzbuhler B, 2018, EUR J NUCL MED MOL I, V45, P20, DOI 10.1007/s00259-017-3850-x
· Kratochwil C, 2016, J NUCL MED, V57, P1941, DOI 10.2967/jnumed.116.178673
· Lindenberg L, 2016, SEMIN NUCL MED, V46, P536, DOI 10.1053/j.semnuclmed.2016.07.001
· Lindenberg L, 2016, J NUCL MED, V57, p111S, DOI 10.2967/jnumed.115.169763
· Maurer T, 2016, NAT REV UROL, V13, P226, DOI 10.1038/nrurol.2016.26
· Maurer T, 2016, J UROLOGY, V195, P1436, DOI 10.1016/j.juro.2015.12.025
· Messiou C, 2009, BRIT J CANCER, V101, P1225, DOI 10.1038/sj.bjc.6605334
· Mottaghy FM, 2016, EUR J NUCL MED MOL I, V43, P1397, DOI 10.1007/s00259-016-3389-2
· Oto A, 2011, AM J ROENTGENOL, V197, P1382, DOI 10.2214/AJR.11.6861
· Padhani AR, 2017, EUR UROL, V71, P81, DOI 10.1016/j.eururo.2016.05.033
· Perera M, 2016, EUR UROL, V70, P926, DOI 10.1016/j.eururo.2016.06.021
· Perez-Lopez R, 2017, RADIOLOGY, V283, P168, DOI 10.1148/radiol.2016160646
· Pyka T, 2016, EUR J NUCL MED MOL I, V43, P2114, DOI 10.1007/s00259-016-3435-0
· Roach PJ, 2018, J NUCL MED, V59, P82, DOI 10.2967/jnumed.117.197160
· Salminen E, 2002, ACTA ONCOL, V41, P425, DOI 10.1080/028418602320405005
· Schlenkhoff CD, 2016, CLIN NUCL MED, V41, P423, DOI 10.1097/RLU.0000000000001158
· Schwarzenboeck SM, 2017, J NUCL MED, V58, P1545, DOI 10.2967/jnumed.117.191031
· Seitz AK, 2018, EUR J NUCL MED MOL I, V45, P602, DOI 10.1007/s00259-017-3887-x
· Song I, 2010, AM J ROENTGENOL, V194, pW477, DOI 10.2214/AJR.09.3557
· Tombal B, 2012, ADV UROL, DOI 10.1155/2012/893193
· Tosoian JJ, 2017, NAT REV UROL, V14, P15, DOI 10.1038/nrurol.2016.175
· Uprimny C, 2017, EUR J NUCL MED MOL I, V44, P941, DOI 10.1007/s00259-017-3631-6
· Vargas HA, 2012, RADIOLOGY, V262, P26, DOI 10.1148/radiol.11101996
· Verburg FA, 2016, EUR J NUCL MED MOL I, V43, P397, DOI 10.1007/s00259-015-3240-1
· von Klot CAJ, 2017, NUCL MED MOLEC IMAG, V51, P314, DOI 10.1007/s13139-017-0476-7
· Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
· Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869
· Yu YS, 2015, ONCOL LETT, V10, P3585, DOI 10.3892/ol.2015.3753
dc.description.index MEDLINE
dc.identifier.eissn 1980-5322
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics